Published in Ann Oncol on April 10, 2013
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst (2015) 2.31
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. Oncotarget (2014) 1.34
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol (2015) 1.19
The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst (2016) 0.90
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Melanoma. N Engl J Med (2006) 8.80
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med (2005) 8.25
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA (2004) 4.36
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Cutaneous melanoma. Lancet (2005) 3.94
Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer (1996) 3.53
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer (2004) 3.46
Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci (2008) 3.14
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86
Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol (2010) 2.80
Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol (2008) 2.79
Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol (2006) 2.73
Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res (2010) 2.56
Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol (2009) 2.36
Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer (2008) 2.35
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol (2010) 1.95
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood (2008) 1.74
Melanoma genetics and the development of rational therapeutics. J Clin Invest (2005) 1.50
Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer (2009) 1.48
BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One (2011) 1.40
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer (2011) 1.37
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res (2012) 1.29
Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res (2012) 1.20
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer (2012) 1.18
Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res (2008) 0.99
Multi-sample pooling and illumina genome analyzer sequencing methods to determine gene sequence variation for database development. J Biomol Tech (2010) 0.98
Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Pat Anticancer Drug Discov (2008) 0.85
KIT mutations in ocular melanoma: frequency and anatomic distribution. Mod Pathol (2011) 0.78
Temozolomide for advanced, metastatic melanoma. J Clin Oncol (2000) 0.77
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
The biology of chronic myeloid leukemia. N Engl J Med (1999) 4.80
Biochemistry and pathology of radical-mediated protein oxidation. Biochem J (1997) 3.14
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol (1999) 2.94
Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer (2007) 2.71
HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A (2001) 2.54
Sputum microscopy results at two and three months predict outcome of tuberculosis treatment. Int J Tuberc Lung Dis (1997) 2.53
Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A (2001) 2.39
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev (2001) 2.18
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol (1999) 2.17
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst (1998) 2.17
Mycosis fungoides and Sezary syndrome. Blood (1996) 2.15
Diagnostic value of the radioisotope erection penogram for vasculogenic impotence. J Urol (1990) 2.05
Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res (1998) 1.94
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer (2010) 1.90
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am (2006) 1.89
Sweet's syndrome and cancer. Clin Dermatol (1993) 1.88
A precision measurement of the mass of the top quark. Nature (2004) 1.87
"Dieters" and "vomiters and purgers" in anorexia nervosa. Psychol Med (1976) 1.83
Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med (1991) 1.82
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol (1999) 1.78
Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat (2005) 1.74
Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med (1997) 1.71
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol (1999) 1.71
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol (2011) 1.70
Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol (1988) 1.66
Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol (2000) 1.62
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature (1987) 1.61
Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer (2012) 1.61
Myelomatous effusion with poor response to chemotherapy. J Korean Med Sci (2000) 1.60
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett (1999) 1.54
Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med (1997) 1.53
Measurement of the forward-backward charge asymmetry in top-quark pair production. Phys Rev Lett (2008) 1.53
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood (1995) 1.52
Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol (1986) 1.50
Tailored lay health worker intervention improves breast cancer screening outcomes in non-adherent Korean-American women. Health Educ Res (2008) 1.49
Body weight and the pituitary response to hypothalamic releasing hormones in patients with anorexia nervosa. J Clin Endocrinol Metab (1976) 1.49
Restoration of atrial mechanical function after maze operation in patients with structural heart disease. Am Heart J (1998) 1.48
Selective hepatic vascular exclusion versus Pringle manoeuvre in liver resection for tumours encroaching on major hepatic veins. Br J Surg (2012) 1.47
Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A (1985) 1.47
Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis (2001) 1.46
Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. Genes Chromosomes Cancer (1999) 1.45
Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic Biol Med (1999) 1.45
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest (1993) 1.43
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood (2001) 1.43
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis (2008) 1.41
The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology (1985) 1.41
Chronic myelogenous leukemia: a concise update. Blood (1993) 1.40
Herpes simplex virus infections and cimetidine therapy. J Am Acad Dermatol (1988) 1.39
Sweet syndrome in patients with solid tumors. Cancer (1993) 1.38
Is the Wii Fit a new-generation tool for improving balance, health and well-being? A pilot study. Climacteric (2010) 1.37
A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol (1988) 1.36
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol (2012) 1.35
Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Mol Cell (2001) 1.34
Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer (2009) 1.32
Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol (1995) 1.30
Protein hydroperoxides can give rise to reactive free radicals. Biochem J (1995) 1.30
The Saccharomyces cerevisiae TCM62 gene encodes a chaperone necessary for the assembly of the mitochondrial succinate dehydrogenase (complex II). J Biol Chem (1998) 1.28
Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med (1991) 1.28
Tripe palms and malignancy. J Clin Oncol (1989) 1.27
Post-prostatectomy incontinence and the artificial urinary sphincter: a long-term study of patient satisfaction and criteria for success. J Urol (1996) 1.25
Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood (1998) 1.24
Histological and neurotrophic changes triggered by varying models of bladder inflammation. J Urol (2001) 1.22
Cardiovascular disease risk factors in Korean American elderly. West J Nurs Res (2001) 1.20
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J Immunol (2000) 1.20
BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget (2013) 1.20
Sweet's syndrome and malignancy. Am J Med (1987) 1.18
Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol (2011) 1.18
Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood (1987) 1.18
A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med (1990) 1.17
Muir-Torre syndrome. Dermatol Clin (1995) 1.17
Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res (1996) 1.15
Prevalence and factors associated with high blood pressure in Korean Americans. Ethn Dis (2000) 1.15
2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood (1994) 1.14
A case of tranylcypromine ('Parnate') addiction. Br J Psychiatry (1979) 1.13
Vaginal wall sling: long-term outcome analysis of factors contributing to patients satisfaction and surgical success. J Urol (1997) 1.12
Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignancies. Cancer (1991) 1.11
Effects of basic fibroblast growth factor (bFGF) on early stages of tendon healing: a rat patellar tendon model. Acta Orthop Scand (2000) 1.11
Upper limits on a stochastic background of gravitational waves. Phys Rev Lett (2005) 1.11
Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res (1985) 1.10
Measurement of the electron charge asymmetry in pp[over ]-->W+X-->enu+X events at sqrt[s]=1.96 TeV. Phys Rev Lett (2008) 1.09
RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol (1999) 1.09
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer (2012) 1.09
Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther (2000) 1.09
Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther (1995) 1.08
Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res (2000) 1.08
Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med (1993) 1.08
Sequence variation of mitochondrial DNA control region in Koreans. Forensic Sci Int (1997) 1.07
Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes. Eur J Immunol (2000) 1.06